Title:
EGFR TARGETED THERAPY OF NEUROLOGICAL DISORDERS AND PAIN
Document Type and Number:
Japanese Patent JP2022058654
Kind Code:
A
Abstract:
To provide compositions and methods for treatment of neurological disorders, in particular, an epidermal growth factor receptor (EGFR) as a clinical target for treatment of neurological disorders, preferably in conjunction with neuropathic pain.SOLUTION: The compositions contain EGFR inhibitors.SELECTED DRAWING: Figure 1
More Like This:
Inventors:
CHRISTIAN KERSTEN
MARTE GAROENLIE CAMERON
SVEIN MJAELAND
MARTE GAROENLIE CAMERON
SVEIN MJAELAND
Application Number:
JP2022006083A
Publication Date:
April 12, 2022
Filing Date:
January 19, 2022
Export Citation:
Assignee:
SYKEHUSET SORLANDET HF
International Classes:
A61K45/00; A61K31/167; A61K31/197; A61K31/44; A61K31/517; A61K31/5377; A61K39/395; A61P25/02; A61P25/04; A61P29/00; A61P43/00
Domestic Patent References:
| JP2010505773A | 2010-02-25 | |||
| JP2007532566A | 2007-11-15 |
Other References:
KERSTEN CHRISTIAN, BMJ CASE REPORTS ENGLAND, JPN5016000520, 14 June 2012 (2012-06-14), pages 1 - 6, ISSN: 0004979592
HUANG, SHYHMIN ET AL.: "Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR): Combining Anti-EGFR A", CANCER RESEARCH, vol. 64, no. 15, JPN7017002809, 2001, pages 5355 - 5362, XP002399541, ISSN: 0004979593, DOI: 10.1158/0008-5472.CAN-04-0562
HUANG, SHYHMIN ET AL.: "Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR): Combining Anti-EGFR A", CANCER RESEARCH, vol. 64, no. 15, JPN7017002809, 2001, pages 5355 - 5362, XP002399541, ISSN: 0004979593, DOI: 10.1158/0008-5472.CAN-04-0562
Attorney, Agent or Firm:
Shinichiro Tanaka
Kenji Asai
Kazuo Yamazaki
Satsuki Ichikawa
Hironobu Hattori
Kenji Asai
Kazuo Yamazaki
Satsuki Ichikawa
Hironobu Hattori
Previous Patent: Methods and systems realized by blockchain
Next Patent: Predictive adjustable hydraulic rails
Next Patent: Predictive adjustable hydraulic rails